Premium
THE PROLONGED USE OF TRIMETHOPRIM/SULPHONAMIDE IN URINARY INFECTION
Author(s) -
DAWBORN J. K.,
CASTALDI P. A.,
KILGOUR A.,
PARKIN J. D.,
PATTISON G.
Publication year - 1973
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1973.tb111189.x
Subject(s) - medicine , neutropenia , platelet , urinary system , bone marrow , eosinophilia , trimethoprim , bone marrow suppression , leukopenia , sulfamethoxazole , urine , gastroenterology , surgery , antibiotics , chemotherapy , microbiology and biotechnology , biology
Fourteen patients with persistent or recurrent urinary infection were treated with trimethoprim‐sulphamethoxazole (TMP/SMX) for at least 12 months. Control of infection was achieved in nine patients during this period. A mild depression of the number of reticulocytes, neutrophils and platelets occurred In most patients, and occasional eosinophilia in the peripheral blood and bone marrow. However, no clinically significant episodes of neutropenia or thrombocytopenia were seen, and no megaloblastic changes observed in the bone marrow. There was improvement in iron utilization in five patients, probably due to control of Infection. Long‐term treatment with TMP/SMX is safe in patients who are not severely ill if preexisting folate deficiency is excluded, and the patient is not receiving other drugs which affect bone marrow function. If continuous treatment is required, the smallest dose which will control infection should be used, and treatment should be monitored with three‐monthly blood films.